Pleading guilty to misbranding one of its heart drugs, Johnson & Johnson's Scios unit has agreed to pay an $85 million fine, according to a Bloomberg report.
Scios was charged in July with misbranding its drug, Natrecor, one of the first drugs for congestive heart failure when approved in 2001, since the drug's label lacked adequate directions for use. Under a plea agreement, Scios will be placed under organizational probation for three years along with the payment of the fine.
While the government agreed not to prosecute Scios or J&J for other offenses related to the marketing of Natrecor, that exemption doesn't apply to False Claims Act liability, according to the report.
Mississippi Wins More Than $38M in Suit Against Sandoz
Justice Department Issues Subpoenas to Merck Over Drug Marketing
Scios was charged in July with misbranding its drug, Natrecor, one of the first drugs for congestive heart failure when approved in 2001, since the drug's label lacked adequate directions for use. Under a plea agreement, Scios will be placed under organizational probation for three years along with the payment of the fine.
While the government agreed not to prosecute Scios or J&J for other offenses related to the marketing of Natrecor, that exemption doesn't apply to False Claims Act liability, according to the report.
Related Articles on Pharmaceutical Companies and Fraud:
New Jersey's Par Pharmaceutical to Pay $154M to Settle Medicaid Fraud AllegationsMississippi Wins More Than $38M in Suit Against Sandoz
Justice Department Issues Subpoenas to Merck Over Drug Marketing